EMERYVILLE, Calif., Sept. 14 /PRNewswire-FirstCall/ -- NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. These two separate laboratory studies of its Aganocide(R) compounds reveal potent activity in killing bacteria that have developed resistance to antiseptics and antibiotics and that the compounds demonstrate rapid bactericidal and anti-biofilm activity in the presence of plasma, serum or albumin.
The two studies conducted by NovaBay scientists advance the company's efforts to provide solutions to the global problem of multidrug-resistant bacteria, which are rapidly diminishing the effectiveness of antibiotics and antiseptics for the treatment and prevention of many common infections. While multi-drug resistance to antibiotics has received much attention over the past few years, resistance to antiseptics is becoming an increasing concern.
"Modern medicine faces an urgent need to develop new classes of drugs that do not develop resistance to antibiotics and antiseptics," said Ron Najafi, president and CEO of NovaBay. "Our Aganocide compounds are an example of such a drug and they are on the bioequivalent of the natural anti-microbial compounds produced in white blood cells that have remained effective against invading pathogens for millions of years."
The first study examined the bactericidal activity of NovaBay's lead Aganoc
|SOURCE NovaBay Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved